top of page

Call to Action

Blue Notes Notebook

To Do Today:

Email Congress - 

- Senator

- Representative

Email/Call Pharma - 

- Avidity

- Sarepta

- Dyne

Share Lucas' Story

with everyone!!

Subject: Please Support Children Living with Rare Muscle Diseases

​

Dear Senator/Representative, (Best to personalize with his/her name)

​

I am writing today to ask for your support for increased federal funding for rare disease and muscular dystrophy research, including Early-Onset Facioscapulohumeral Muscular Dystrophy (FSHD).

​

I recently learned about a local child named Lucas who is living with early-onset FSHD, a rare and progressive muscle-wasting disease. Unlike many adults with FSHD, children with early-onset FSHD often experience a more severe form of the disease that can rapidly take away strength, mobility, and independence during childhood.

​

While promising research is underway, most treatments must first go through adult clinical trials before they can be studied in children. For families facing fast-progressing pediatric diseases, years of waiting can mean irreversible loss of function and opportunities that can never be regained.

​

I respectfully ask that you:

  • Support increased funding for rare disease and muscular dystrophy research.

  • Support legislation that helps accelerate the safe inclusion of pediatric patients in clinical research.

  • Encourage policies that help children gain access to promising therapies as quickly as possible while maintaining appropriate safety standards.

  • Advocate for families affected by rare and life-altering diseases.

​​

Children with early-onset FSHD do not have time to wait. Their disease continues to progress every day. Please help ensure that research, funding, and policy decisions reflect the urgency these families face.

​

Thank you for your service and for supporting children and families impacted by rare diseases.

​

Sincerely,

[Your Name]
[City, State]

Sample Email

Write Your Congress

 

  • Avidity Biosciences

Program: Del-brax (delpacibart braxlosiran) for FSHD, currently in advanced clinical development targeting DUX4. 

  • Website: https://www.aviditybiosciences.com

  • General Email: info@aviditybio.com

  • Phone: (858) 401-7900 
     

Suggested Message:
"Please continue advancing pediatric development plans for children with early-onset FSHD whenever it is safe and scientifically appropriate."
 

  • Sarepta Therapeutics

Program: SRP-1001 (formerly ARO-DUX4), an RNA therapy designed to reduce DUX4 activity in FSHD. 

  • Website: https://www.sarepta.com

  • Main Phone: (617) 274-4000 

  • Contact Page: https://www.sarepta.com/contact-us
     

Suggested Message:
"Children with early-onset FSHD often face more severe disease progression. Please consider pediatric studies as early as possible."
 

  • Dyne Therapeutics

Program: DYNE-302, a DUX4-targeting therapy that recently entered human clinical development. 

  • Website: https://www.dyne-tx.com

  • Contact Page: https://www.dyne-tx.com/contact/
     

Suggested Message:
"Please include early-onset FSHD patients in future development plans whenever supported by the science and safety data."

🧬 Companies Actively Developing FSHD Therapies

Call or Email Pharma & Biotech 

Your voice can help ensure children like Lucas are not left behind. 💙

Youtube video
bottom of page